Development of a new ARCHITECT automated periostin immunoassay

- The new automated periostin immunoassay is performed on the ARCHITECT i System.
- This Investigational Use Only assay reliably measures periostin concentrations.
- This assay detects periostin isoforms known to be expressed in the lung.

BackgroundPeriostin is being investigated as a potential biomarker for T-helper-2 (Th2)-driven asthma or eosinophilic inflammation and may help to identify patients more likely to benefit from interleukin-13-targeted treatments. We report the development and analytic performance of the investigational use only ARCHITECT Periostin Immunoassay, a new automated assay developed to detect serum periostin concentrations.MethodsWe assessed assay performance in terms of precision, sensitivity, linearity, interference from classical immunoassay interferents and representatives of common asthma medications, specimen handling, and isoform reactivity. The assay was also used to assess the biological variability of serum periostin concentrations in samples from healthy volunteers and from subjects with uncontrolled asthma (the intended use population).ResultsThe percentage CVs for 5-day total precision, assessed using two instruments, was < 6% across 2 controls and one serum-based panel. Limit of quantitation was 4 ng/mL (dilution adjusted concentration), suiting the needs for this application. Dilution analysis yielded linear results and no endogenous sample or drug interferences were observed. All known periostin isoforms expressed in the mature human lung were detected by the assay.ConclusionOur studies provide support that the ARCHITECT Periostin Immunoassay is a reliable and robust test for measuring serum periostin concentrations.

183